Apexigen

company

About

Apexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics.

  • 1 - 10

Details

Last Funding Type
Series A
Last Funding Money Raised
$20M
Industries
Biopharma,Biotechnology,Health Care,Pharmaceutical
Founded date
Jan 1, 2010
Number Of Employee
1 - 10
Operating Status
Active

Apexigen is a biopharmaceutical product development company advancing a pipeline of novel product candidates with the potential to address life-threatening and difficult-to-treat diseases. They discover and develop innovative drugs that enhance tumor-specific immunity.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
$20M
Apexigen has raised a total of $20M in funding over 2 rounds. Their latest funding was raised on Aug 6, 2013 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Aug 6, 2013 Series A $20M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Apexigen is funded by 2 investors. WSR Capital and Themes Investment Partners are the most recent investors.
Investor Name Lead Investor Funding Round
WSR Capital Series A
Themes Investment Partners Series A